Advertisement

Irish Journal of Medical Science

, Volume 177, Issue 1, pp 69–71 | Cite as

Propylthiouracil induced C-ANCA positive agranulocytosis complicating Graves’ thyrotoxicosis in pregnancy

  • F. M. Finucane
  • J. O’Connell
  • B. T. Kinsley
Case Report

Abstract

Background

Thionamide induced agranulocytosis is associated with the presence of anti-neutrophil cytoplasmic antibodies (ANCA) in some patients. This poses a particular challenge when it occurs during pregnancy.

Aims

To report a case of a 31-year-old woman with Graves’ disease who presented at 11 weeks gestation with propylthiouracil induced agranulocytosis.

Methods

After cessation of propylthiouracil the patient developed recurrent thyrotoxicosis, and underwent an elective subtotal thyroidectomy at 23 weeks gestation.

Results

The patient required postoperative thyroxine replacement therapy. Subsequent pregnancy was uneventful and she delivered a healthy baby boy at 41  weeks gestation. As part of our routine work up for agranulocytosis we measured C-ANCA levels, which were significantly elevated.

Conclusion

This case highlights the association of propylthiouracil induced ANCA positivity and agranulocytosis. Second trimester subtotal thyroidectomy was safe and effective in treating this pregnant patient’s thyrotoxicosis.

Keywords

Agranulocytosis Pregnancy Propylthiouracil Thionamide Thyrotoxicosis 

References

  1. 1.
    Ghaneim A, Atkins P (1998) Management of thyrotoxicosis in pregnancy. Int J Clin Pract 52(1):36–8PubMedGoogle Scholar
  2. 2.
    Masiukiewicz US, Burrow GN (1999) Hyperthyroidism in pregnancy: diagnosis and treatment. Thyroid 9(7):647–52PubMedCrossRefGoogle Scholar
  3. 3.
    Davis LE, Lucas MJ, Hankins GD, Roark ML, Cunningham FG (1989) Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol 160(1):63–70PubMedGoogle Scholar
  4. 4.
    Senior B, Chernoff HL (1971) Iodide goiter in the newborn. Pediatrics 47(3):510–5PubMedGoogle Scholar
  5. 5.
    Baeza A, Aguayo J, Barria M, Pineda G (1991) Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf) 35(5):439–42CrossRefGoogle Scholar
  6. 6.
    Davison S, Lennard TW, Davison J, Kendall-Taylor P, Perros P (2001) Management of a pregnant patient with Graves’ disease complicated by thionamide-induced neutropenia in the first trimester. Clin Endocrinol (Oxf) 54(4):559–61CrossRefGoogle Scholar
  7. 7.
    Glinoer D (1997) The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 18(3):404–33PubMedCrossRefGoogle Scholar
  8. 8.
    Roti E, Minelli R, Salvi M (1996) Clinical review 80: Management of hyperthyroidism and hypothyroidism in the pregnant woman. J Clin Endocrinol Metab 81(5):1679–82PubMedCrossRefGoogle Scholar
  9. 9.
    Tajiri J, Noguchi S (2004) Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid 14(6):459–62PubMedCrossRefGoogle Scholar
  10. 10.
    Helfgott SM, Smith RN (2002) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2002. A 21-year-old man with arthritis during treatment for hyperthyroidism. N Engl J Med 347(2):122–30PubMedCrossRefGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2007

Authors and Affiliations

  • F. M. Finucane
    • 1
  • J. O’Connell
    • 1
  • B. T. Kinsley
    • 1
  1. 1.Department of Endocrinology and Diabetes MellitusMater Misericordiae HospitalDublin 7Ireland

Personalised recommendations